Analyst Price Targets — ONC
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 26, 2026 8:23 pm | Leonid Timashev | RBC Capital | $425.00 | $322.37 | StreetInsider | BeOne Medicines (ONC) PT Raised to $425 at RBC Capital |
| February 4, 2026 10:45 am | — | Barclays | $394.00 | $346.38 | TheFly | BeOne Medicines price target raised to $394 from $385 at Barclays |
| January 12, 2026 10:52 am | — | Bernstein | $414.00 | $337.89 | TheFly | BeOne Medicines upgraded to Outperform from Market Perform at Bernstein |
| January 8, 2026 12:42 pm | — | Morgan Stanley | $405.00 | $333.87 | TheFly | BeOne Medicines price target raised to $405 from $390 at Morgan Stanley |
| November 24, 2025 12:30 pm | — | Truist Financial | $400.00 | $347.72 | TheFly | BeOne Medicines initiated with a Buy at Truist |
| November 17, 2025 8:19 pm | — | Jefferies | $420.00 | $376.63 | TheFly | BeOne Medicines price target raised to $420 from $398 at Jefferies |
| October 20, 2025 1:14 pm | Sean Laaman | Morgan Stanley | $383.00 | $319.19 | TheFly | BeOne Medicines price target raised to $383 from $350 at Morgan Stanley |
| September 18, 2025 8:34 am | — | Barclays | $385.00 | $337.43 | TheFly | BeOne Medicines initiated with an Overweight at Barclays |
| March 13, 2025 10:58 am | — | Bernstein | $259.00 | $254.57 | TheFly | BeiGene price target raised to $259 from $207 at Bernstein |
| February 28, 2025 12:24 pm | — | JMP Securities | $348.00 | $271.80 | TheFly | BeiGene price target raised to $348 from $288 at Citizens JMP |
Latest News for ONC
BeOne Medicines remains a strong buy despite a modest 2026 guidance miss, with a $410/share 12-month price target. Brukinsa's 49% YoY growth to $3.93B in 2025 and best-in-class CLL data underpin ONC's market leadership and profitability inflection. Imminent catalysts include potential FDA approvals for Sonrotoclax (BCL2 inhibitor) and BTK-CDAC (BTK degrader), both poised to drive substantial upside in 2026.
Artisan Partners Limited Partnership reduced its stake in BeOne Medicines Ltd. - Sponsored ADR (NASDAQ: ONC) by 7.5% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 249,844 shares of the company's stock after selling 20,309 shares during the quarter.
The headline numbers for BeOne Medicines Ltd. - Sponsored ADR (ONC) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the fourth quarter and full year 2025. “These strong financial results for the fourth quarter and full year 2025 underscore our continued evolution as a global oncology leader with durable competitive advantages in…
Pick any major technology that could shape the future, and there's a good chance Alphabet is already a leader in it. Buying Amazon shares on pullbacks has always paid off handsomely over the long run.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ONC.
U.S. House Trading
No House trades found for ONC.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.